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Pulmonary disease causedbyMycobacteriumxenopi
in HIV-negative patients: ¢ve year follow-up of
patients receiving standardised treatment
P.A. JENKINS, I.A.CAMPBELL ANDRESEARCH COMMITTEE OF THE BRITISH THORACIC SOCIETY
Llandough Hospital,Cardi¡,Vale of Glamorgan,UK
Abstract The literature concerning themanagementof pulmonarydisease caused byMycobacteriumxenopi is scanty
andconsistsofretrospectivereports,mostlyof small seriesofpatients.Our aimwas to documentthe clinical features and
response to treatmentof this rare butchallenging disease.Patientswere treated in a randomised, multi-centre trialwith
either rifampicin plus ethambutol or rifampicin, ethambutol and isoniazid.Clinical, bacteriological and radiological pro-
gress wasmonitored at set intervals for 5 years. As no differences emerged between the two groups, the results have
beencombinedtoprovidethisprospective survey.Forty-twopatientswere studied.Meanagewas 65 years, three-quar-
ters were male and two-thirds had other lung disease(s). Sputumwas positive on direct smear in 62%.Cavitation was
present in 81%, mostly large cavities, and diseasewas extensive in 38%.Despite good clinical response and little toxicity
the death ratewas high (69%), but less than10% died primarily because of theM.xenopi disease.The failure of treatment/
relapse rate was 12%.Only11 (26%) were known to be alive at 5 years of whom seven (17%) were known to be cured.
There was no correlation between failure of treatment/relapse and in vitro resistance. Better methods of susceptibility
testingandmore effectiveregimens areneeded, butitis also evidentthatimprovedmanagementofconcomitant diseases
and better generalhealthwillplay amajor part in increasing survival.r2003 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2002.1444, available online at http://www.sciencedirect.com
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Pulmonary disease caused by opportunist mycobacteria
accounts for approximately 5% of mycobacterial pul-
monary disease in U.K.Of the opportunist mycobacter-
ial infectionsM. xenopi is the least common, except in the
South East of England, where of 533 new opportunist
mycobacterial infections registered at the Mycobacter-
ium Reference Laboratory in Dulwich, 37% were due to
M. xenopi (1).The symptoms and signs of pulmonary dis-
ease caused by M. xenopi do not di¡er from those ofM.
tuberculosis or of the other opportunist mycobacterial
pulmonary infections. Radiologically the appearancesReceived 9 August 2002, accepted in revised form 20 August 2002.
The study was co-ordinatedby a Sub-Committee of the Research
Committeewhosemembers were: Drs P. A. Jenkins (Chairman), J.
Banks, I. A.Campbell (Co-ordinating Physician and Compiler of the
Report),C.M.Gelder, R. J. Prescott (Statistician) and A. P. Smith.
Correspondence should be addressed to:Dr I. A.Campbell, Llandough
Hospital, Penlan Road, Penarth,Vale of Glamorgan,CF64 2XX,UK.
Fax: +44 (0) 29 2035 0056; E-mail: ian.campbell@lhct-tr.wales.nhs.ukare indistinguishable from those ofpulmonary tuberculo-
sis (2^5).
The British Thoracic Society has conducted a multi-
centre, randomised trial of two regimens of chemother-
apy in the treatment of lung disease caused byM. xenopi,
the ¢rst prospective study of the treatment of this con-
dition. Patients were followed for 3 years after comple-
tion of 2 years’chemotherapy with either rifampicin and
ethambutol or rifampicin, ethambutol and isoniazid. Pa-
tientdemographics at entry to the trial and the results of
treatment did not di¡er signi¢cantly between the two
regimens (6).Combining the results from the two treat-
ment groups provides the ¢rst, prospective, controlled
survey of the long-term outcome in patients receiving
treatment forM. xenopi pulmonary disease.
METHODS
The patients studied were aged 16 years or older, had
sputum which was positive on culture for M. xenopi on
440 RESPIRATORYMEDICINEat least two occasions separated by at least a week, had
radiographic changes compatiblewithmycobacterial pul-
monary disease and/or clinical evidence of such disease.
Patients known to be HIV+ were not included nor were
pregnant women, those with terminal or pre-terminal
disease, psychoses, previous intolerance to one ormore
of the trial drugs or with active co-infection withM. tu-
berculosis orM. bovis.
For those in whom anti-tuberculosis chemotherapy
had been started before the true diagnosis was known,
drugs other than rifampicin and ethambutol were dis-
continued, except that half the patients continued/re-
ceived isoniazid as well. The dose of rifampicin was
600mg daily for patients weighing 50kg and over and
450mg daily for those who weighed less than 50mg.
Ethambutol was given in a dose of 15mg per kg and iso-
niazid as 300mg daily.Chemotherapy was continued for
2 years.
Age, sex, weight, BCG status, occupational exposure
to dust, previous pulmonary disease(s) and any condi-
tions likely to impair immune defences, e.g. diabetesmel-
litus, rheumatoid arthritis, lymphoma, leukaemia,
therapy with corticosteroids and/or immunosuppressive
drugs were recorded. These data were sent to the Co-
ordinating Physician, together with the pre-treatment
chest radiograph.This and subsequent radiographs were
read by the Co-ordinating Physician, using a standard
method of grading extent of disease and cavitation (7).
In vitro sensitivity tests to individual drugs (rifampicin,
ethambutol, isoniazid) were performed by the national
Mycobacterium Reference Units (MRU) for U.K. and
Scandinavia, using the modal resistance method devel-
oped forM. tuberculosis (8,9).
During the 2 years of chemotherapy, thephysicianwas
asked to review the patient every 3 months, judging clin-
ical progress as satisfactory or not, recording also
weight, tolerance to chemotherapy and con¢rmation of
its prescription. Two specimens of sputum were re-
quested at each review, to be sent to the MRUs. Chest
radiographs were requested at 3, 6, 12 and 24 months
from the beginning of the trial regimen. A reminder to
discontinue chemotherapy was sent with the reviewTABLE 1. Pre-treatmentcharacteristics of patientswith pulmon
Sex 32 M,10 F
Mean age
(range)
65 year
(30^84 year)
Previous lungdisease 28 (66%)
Reduced immunity 11 (26%)
Dusty 7 (17%)
BCG 1 (2%)form at 24 months. If the patient’s sputumwas still posi-
tive on culture at 21months, extra specimens were col-
lectedbetween 21months and 24months. If any of these
provedpositive thepatientwas categorised as a‘failure of
treatment’and furthermanagementwas at the discretion
of the physician.
After completing chemotherapy patients were re-
viewed clinically and bacteriologically (two specimens of
sputum) every 6 months for 5 years. Chest radiographs
were requested annually. Those whose sputum became
positive on culture (two specimens separated by at least
2 weeks) were classed as relapses. Further management
was left to the discretion of the physician.
Patients with negative cultures in the last 3 months of
treatment and whose sputum remained negative on cul-
ture for the subsequent 3 years were classed as cured.
If a patient died during his/her period in the study, the
cause of deathwas ascertained from thephysician and/or
general practitioner and/or post-mortem report. Using
these sources, deaths were classi¢ed by the Co-ordinat-
ing Physician as primarily caused either by the mycobac-
terial lung disease or not so caused.
After the trial was completed enquires were made of
the consultant and/or general practitioner in order to
try to ascertain whether the patients lost from follow-
up during the trial were alive at 5 years or not.
RESULTS
Forty-two patients (22 RE, 20 REH) were entered (40
British, 2 Scandinavian) in just over 5 years, three-quar-
ters of whomweremale (Table1).Mean agewas 65 years,
range 30^84 years.Two-thirds had previous or co-exist-
ing lung disease(s), mostly chronic bronchitis and emphy-
sema or asthma (13), healed tuberculosis (5), pneumonia
(4) and bronchiectasis (3).Conditions likely to impair im-
mune response were recorded in 11 (26%) and seven
(17%) of the 42 had previously worked in dusty occupa-
tions.Only one patientwas known to have had BCGvac-
cination. Sputum was positive on direct smear in 26
(62%) patients (Table1).arydisease caused byM. xenopi (n=42)
Direct smear +ve 26 (62%)
Cavitation 34 (81%)
Unilateral disease 23 (55%)
Upper zone(s) only 19 (45%)
Three zones ormore 16 (36%)
Other pulmonarydiseases
evidenton CXR
27 (64%)
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Clinical progress was recorded on 256 occasions, on 213
(83%) of which it was gradedby the physician as satisfac-
tory.Of the 43 times that clinical progress was regarded
as unsatisfactory, 14 (5% of all 256 recordings) were at-
tributed to the M. xenopi disease.There were three fail-
ures of treatment (two of whom died later) and two
relapses after the end of treatment (Table 2 and Fig. 1).
In two patients (5%) outcome is not known.Only seven
patients (17%) were known to be alive and cured at 5
years.Of the four others alive at 5 years three had ear-
lier been failures of treatment or relapses.The bacteriolo-
gical status of the fourth could not be ascertained, but
he had not sought treatment again from his original phy-
sician for mycobacterial disease. Eight patients (19%) hadTABLE 2. M. xenopipulmonarydisease: results duringand after
RE
No. patients 22
Outcomeunknown 1
No. alive at 5 years 9
No. deaths (all causes) 12
No. died because
ofM. xenopi
0
No. failures of treatment
andrelapses
41D
No. who completed treatment
as allocated andwereknownto
be alive and cured at 5 years
5
D, died.
FIG. 1. Outcome over 5 years.a poor outcome of their mycobacterial disease (failure of
treatment, relapse or death because of themycobacterial
disease). No signi¢cant association was found for any
variable in relation to poor outcome or to survival.
Within 5 years of diagnosis 69% had died, but only
three of the 29 deaths (7% of the total entry to the
study) were primarily attributed to the mycobacterial
disease (Table 2). Of the remaining 26 deaths, six were
caused by lung cancer, four by pneumonia, ¢ve by re-
spiratory failure not attributable to M. xenopi, three by
ischaemic heart disease, one by stroke and in seven pa-
tients the causes of deathwere not available.
The results of in vitro susceptibility testswere available
for 29 patients and indicate that whereas one-third of
the organismswereresistant to rifampicin, 86%were re-
sistant to isoniazid and 70% were resistant totreatment
REH Total (%)
20 42
1 2 (5%)
2 11 (26%)
17 29 (69%)
3 3 (7%)
11D 52D (12%)
2 7 (17%)
442 RESPIRATORYMEDICINEethambutol.There was no correlation between failure of
treatment/relapse and in vitro resistance to those drugs
(Table 3).
Radiological results
Cavitation was found in 34 (81%), and 25 patients (60%)
had at least one cavity of 2 cm or more in diameter. Just
over half (55%) showedunilateral disease.Three ormore
lung zones were involved in 36%, whilst in 45% disease
was con¢ned to theupper zone(s). In 64% other pulmon-
ary diseases were radiologically evident and in four
further patients therewere changes indicating combina-
tions of cardiac andpulmonary or pleural andpulmonary
disease(s).
At 5 years cavitation was still evident in seven of the
ten patients radiographed, slightly less than on entry
(81% of all 42 patients), and there had been reductions in
the number of lung zones involved by the end results of
the disease as comparedwith the appearances at the be-
ginningof treatment in four of these ten. In eightpatients
with a complete set of yearly radiographs up to 5 years,
25%were classed as radiologically healed at 3 years, 88%
at 4 years and100% at 5 years (Table 4).
DISCUSSION
This paper reports the results at 5 years of the ¢rst pro-
spective survey of the clinical features and response to
treatment of patients with pulmonary disease caused by
M. xenopi.The survey was controlled in that patients re-TABLE 3. In vitro susceptibilityin relationto failure of treatment/
Failure oftreat
Rifampicin Resistant 2
Sensitive 3
Ethambutol Resistant 3
Intermediate 1
Sensitive 1
Isoniazid Resistant 5
Intermediate 0
Sensitive 0
TABLE 4. M. xenopipulmonarydisease: radiologicalhealing in t
Year One Two (end oftreatmen
Healed None Noneceivedone of two regimens for 2 years, with clinical, bac-
teriological and radiological information obtained at
standard intervals during chemotherapy and for 3 years
after the end of chemotherapy.Forty-two patients were
studied, a numberconsiderablygreater than in theretro-
spective series reportedby Costrini et al. (10), Smith and
Citron (11) and Contreras et al. (12), but slightly less than
the number described by Banks et al. (13). As the retro-
spective reports adequately documented the presenting
symptoms and signs of this condition, which are much
like those of pulmonary tuberculosis (11^13), these were
not recorded in the survey.
Clinical progresswhile alivewas on thewhole satisfac-
tory, andmore so than found in the earlier studieswhere
relatively toxic, multiple-drug regimens, which did not
always contain rifampicin andethambutol, hadbeenused
because of the result of in vitro sensitivity tests (12,13).
The authors of two of the retrospective reports com-
mented on the fact that in their patients the response
to treatment appeared not to correlate with the results
of susceptibility tests (11,13).We have con¢rmed that in
this disease the results of such tests, performed by the
standard modal resistance technique and using single
antimycobacterial drugs, do not predict response in the
sameway as theydo fordisease causedbyM. tuberculosis.
Synergy between rifampicin and ethambutol, noted by
Banks and Jenkins (14), could explain this ¢nding. Never-
theless at 5 years only 17% of the original 42 patients
were known to be alive and cured of theirM. xenopi dis-
ease.This is less than Contreras et al. reported (29% of
34 patients) (12) and less than that found in the two
British reports (72 and 23%) (11,13) but in these threerelapse
ment/relapse Other
8 w2 = 0.05
16 P= 0.82
17 w2 trend = 0.001
0 P = 0.97
7
20 w 2 trend = 0.83
2 P= 0.36
2
he eightpatientswith a complete setof radiographs to 5 years
t) Three Four Five
2 7 8
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periods whichwere usually shorter than 5 years.
The death rate of 69% within 5 years was remarkable:
it is higher than the 30^40% found in two retrospective
series (12,13) and is almost six times that expected in the
general population of similar age.M. xenopi is associated
with much higher mortality than the other species of
opportunistmycobacteria (4,15,16), butonly 7%of ourpa-
tients were judged to have diedbecause of theM. xenopi
disease, less than in the Canadian report (15%) (12) and
the earlier British report (20%) (13). It should be appre-
ciated that whilst as good a judgement wasmade as was
possible in the circumstances of the trial, deciding the
precise cause of death is not always easy in a population
such as this. The generally high death rates in patients
with M. xenopi pulmonary disease presumably re£ect
the presence of concomitant diseases. It is likely that
the organism opportunistically infects frailer individuals
who later succumb to their underlying illnesses rather
than to the mycobacterial disease. An alternative expla-
nation couldbe a systemic e¡ect of this particular organ-
ism.
Malespredominated (75%) as theyhaddone in the ear-
lier series (80^100%) (10^13).Mean age (65 years) and the
range of age (30^84 years) was much as described in
three of the previous reports (11^13), but greater than in
the fourth (56, range 45^67 years) (10): clearly, thepopu-
lation with this disease is mostly middle-aged to elderly
andmostlymale, as is the case for the other opportunist
mycobacterial species (4,15,16). Underlying lung disease
was noted in two-thirds of the patients, fewer than re-
ported in the North American (84%) and Canadian
(100%) series (10,12), but much closer to the 74 and 75%
in the two British retrospective reports (11,13). Chronic
bronchitis and emphysema predominated on both sides
of the Atlantic. Costrini et al. found diabetes mellitus
and/or alcohol abuse in 18 of 19 patients (10) while Con-
treras et al. found alcohol abuse and/or a history of pre-
vious gastrectomy in 28 of 34 patients (12). Banks et al.
commented that six of their 47 patients had previous
gastrectomies (13) but the other British report men-
tioned only one of15 (11). A quarter of our patients had a
condition likely to impair immune response but none
were known to be HIV positive.The four retrospective
reports antedate the HIV era, but even during the HIV
eraM. xenopi has rarely infected such patients (17).
Cavitation was common: our 81% tallied closely with
the percentages quoted in three of the retrospective re-
ports (73^100%) (11^13), butCostrinietal. foundit inonly
half of their group of 19 (10). The cavities tended to be
large rather than small (60%42 cm in diameter). Unilat-
eral diseasewas present in just over half of our patients,
much as itwas foundby Banks et al. (13) but in theNorth
American and Canadian series bilateral disease was
more common (60^85%) (10,12).We didnot ¢nd the pre-
dominance of upper zone changes noted by Contreraset al. (12) and Smith and Citron (11), but we agree that
the radiographic characteristics in M. xenopi pulmonary
disease are not speci¢c enough to allow di¡erentiation
fromdisease causedbyM. tuberculosis or byother oppor-
tunist mycobacterial infections (2,4,5,18).Comparison of
theradiologicalresponses during this study with thepre-
vious studies is di⁄cult because those studies were ret-
rospective, had varying durations of follow-up, did not
assess radiological changes at set points in time nor use
de¢ned methods of categorising changes on the radio-
graph. All that can be said is that the previous authors
noted a general trend towards improvement in the radi-
ological appearances (10,11,13) with one of the reports
commenting that cavities rarely closed completely (13).
Our ¢ndings provide for the ¢rst time radiological re-
sults in a format that can be used as a basis for future
reference.
Wewere unable to demonstrate a signi¢cant associa-
tion between any variable and survival, but only 42 pa-
tients entered the study. Any study on relatively
uncommon conditions is always prone to problems with
sample sizeswhich are low, resulting in diminishedpower
to detect associations, or to identify prognostic factors.
Additionally, there is the inferential di⁄culty that many
candidate variables for inclusion in examination of asso-
ciations raise the multiple testing problem, whereby we
can expect 1 in 20 of signi¢cance tests to give P-values
less than 0.05 when there are no genuine associations.
The trial has not addressed the place of surgery in
management: unilateral disease was present in just over
half of our patients, but other data that would provide
insight into operability werenotrecorded. It is likely that
respiratory and cardiac co-morbidity would reduce
further the number in whom surgery could be underta-
ken, but it should nevertheless be borne in mind as an
option for those who do not respond satisfactorily to
chemotherapy. During the period of this study, macro-
lides and quinolones were shown to have in vitro activity
against opportunist mycobacteria (19^23). It remains to
be seenwhether adding one or other or both to rifampi-
cin and ethambutol can improve the results of the treat-
ment of infectionwithM. xenopi.These questions should
be answered by the multi-centre trial currently in pro-
gress under the auspices of the BritishThoracic Society.
Our ¢nding that in vitro susceptibility to an individual
anti-mycobacterial drug does not predict the clinical re-
sponse to that drug underlines the importance of rando-
mised, controlled clinical trials in assessing the place of
any new drug.
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